Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma

Journal of Surgical Oncology

Volumn 111, Issue 6, 2015, Pages 771-775

  Joglekar, Savita ^a   Asghar, Aeen ^a   Mott, Sarah L ^a   Johnson, Benjamin E ^a   Button, Anna M ^a   Clark, Eve ^a   Mezhir, James J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

complications; pancreatectomy; pancreatic cancer; sarcopenia

Indexed keywords

CALCULATION; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HOSPITAL ADMISSION; HOUNSFIELD UNIT AVERAGE CALCULATION; HUMAN; INFECTIOUS COMPLICATION; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PSOAS MUSCLE; RETROSPECTIVE STUDY; SARCOPENIA; STOMACH EMPTYING; SURVIVAL; WOUND; ADENOCARCINOMA; BLOOD TRANSFUSION; COMPLICATION; JEJUNOSTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; UTILIZATION;

ADENOCARCINOMA; BLOOD TRANSFUSION; FEMALE; GASTRIC EMPTYING; HUMANS; INTENSIVE CARE UNITS; JEJUNOSTOMY; LENGTH OF STAY; MALE; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SARCOPENIA;

EID: 84928141278     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23862     Document Type: Conference Paper

References (33)

1. Shaib Y, Davila J, Naumann C, et al.: The impact of curative intent surgery on the survival of pancreatic cancer patients: A U. S. Population-based study. Am J Gastroenterol. 2007; 102: 1377-1382.
2. Winter JM, Brennan MF, Tang LH, et al.: Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol 2012; 19: 169-175.
3. Sun RC, Button AM, Smith BJ, et al.: A comprehensive assessment of transfusion in elective pancreatectomy: Risk factors and complications. J Gastrointest Surg 2013; 17: 627-635.
4. Mezhir JJ,: Management of complications following pancreatic resection: An evidence-based approach. J Surg Oncol 2013; 107: 58-66.
5. Grobmyer SR, Pieracci FM, Allen PJ, et al.: Defining morbidity after pancreaticoduodenectomy: Use of a prospective complication grading system. J Am Coll Surg 2007; 204: 356-364.
6. Lewis R, Drebin JA, Callery MP, et al.: A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2013; 15: 49-60.
7. Van Buren G, 2nd, Bloomston M, Hughes SJ, et al.: A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg 2014; 259: 605-612.
8. Petermann D, Demartines N, Schafer M,: Severe postoperative complications adversely affect long-term survival after R1 resection for pancreatic head adenocarcinoma. World J Surg 2013; 37: 1901-1908.
9. van der Gaag NA, Harmsen K, Eshuis WJ, et al.: Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death. Eur J Surg Oncol 2014; 40: 551-558.
10. Merkow RP, Bilimoria KY, Tomlinson JS, et al.: Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2013; 26: 372-377.
11. Valle JW, Palmer D, Jackson R, et al.: Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014; 32: 504-512.
12. Oettle H, Neuhaus P, Hochhaus A, et al.: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481.
13. Kneuertz PJ, Pitt HA, Bilimoria KY, et al.: Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 2012; 16: 1727-1735.
14. Vollmer CM, Jr., Sanchez N, Gondek S, et al.: A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012; 16: 89-102. discussion 102-103.
15. Christians KK, Tsai S, Mahmoud A, et al.: Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm. Oncologist 2014; 19: 266-274.
16. Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
17. Dale W, Hemmerich J, Kamm A, et al.: Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: A prospective cohort study. Ann Surg 2014; 259: 960-965.
18. Kim SW, Han HS, Jung HW, et al.: Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA Surg 2014; 7: 633-640.
19. Kim TN, Choi KM, Sarcopenia: Definition, epidemiology, and pathophysiology. J Bone Metab 2013; 2 1-10.
20. Englesbe MJ, Patel SP, He K, et al.: Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211 271-278.
21. Peng PD, van Vledder MG, Tsai S, et al.: Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13: 439-446.
22. Itoh S, Shirabe K, Matsumoto Y, et al.: Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol 2014; 10: 3063-3068.
23. Reisinger KW, van Vugt JL, Tegels JJ, et al.: Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg 2014. [Epub ahead of print].
24. Peng P, Hyder O, Firoozmand A, et al.: Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16: 1478-1486.
25. Antoun S, Birdsell L, Sawyer MB, et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study. J Clin Oncol 2010; 28: 1054-1060.
26. Dodson RM, Firoozmand A, Hyder O, et al.: Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013; 17: 2123-2132.
27. Tan BH, Birdsell LA, Martin L, et al.: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15: 6973-6979.
28. Lu CW, Yang KC, Chang HH, et al.: Sarcopenic obesity is closely associated with metabolic syndrome. Obes Res Clin Pract 2013; 7: e301-e307.
29. House MG, Fong Y, Arnaoutakis DJ, et al.: Preoperative predictors for complications after pancreaticoduodenectomy: Impact of BMI and body fat distribution. J Gastrointest Surg 2008; 12: 270-278.
30. Aubrey J, Esfandiari N, Baracos VE, et al.: Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf) 2014; 210: 489-497.
31. Fearon K, Strasser F, Anker SD, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.
32. Lee GC, Fong ZV, Ferrone CR, et al.: High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy. J Gastrointest Surg 2014; 18: 1760-1769.
33. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.